-
Raith Medical expects a first-half loss of $55 million to $85 million
Time of Update: 2021-02-28
On the evening of August 6th, Ruixi Medical (01526, HK), one of the giants of the private medical examination industry, announced its results forecast for the first half of 2018, with net losses of between RMB55 million and RMB85 million (the same as under units), a significant increase over the same period last year.
-
Tiansli Pre-IPO round has the highest valuation, being the largest unicorn in the domestic biopharmaceon field
Time of Update: 2021-02-28
("Tiansli Bio"), an innovative biopharmaceutical company with a listed heavy-weight product in the cardiovascular sector and the industry's ability to develop pipelines, announced the completion of the Pre-IPO round of financing, with a post-investment valuation of 12.5 billion yuan ($1.9 billion).
-
Four-price HPV half-year sales of 2.62 million Zhifei biological net profit increased 297%
Time of Update: 2021-02-28
Up to now, four-price HPV has been in the country's 29 provincial units winning the bid, promotion, sales work is also under way.
-
Liaoning Chengda Bio to Hong Kong IPO: Gross margin is more than 80%
Time of Update: 2021-02-27
end of 2014, Chengda Bio is listed on the new three boards, is currently an innovative layer of enterprises, the transfer mode is "market transfer." With many enterprises landing on the new three boards after the "zero transaction, no financing" situation is different, into the big creatures many times the daily turnover of more than 10 million yuan, in addition to the success of a new issue, raising a net 266 million yuan.
-
More than 9 months after breaking up with Pfizer, Haizheng Pharmaceuticals has re-emerged out of stock
Time of Update: 2021-02-27
An exclusive letter to experts from a reporter for Securities Daily, a communication note on the temporary tight supply of Rui Yining (hereinafter referred to as the Communication Note), shows that Reynin's semi-finished medicine is manufactured by Pfizer's Puerto Rico plant, which was severely affected by Hurricane Maria and suffered serious damage to production capacity.
-
Fangsheng Pharmaceuticals decided to buy a 51% stake in Sanhua Pharmaceuticals for $10.2 million
Time of Update: 2021-02-27
Fangsheng Pharmaceuticals said that the company intends to obtain a controlling stake in Sanhua Pharmaceuticals through the transfer of equity, is conducive to further enrich the tablet, dispersant dosage form product category, improve comprehensive competitiveness, accelerate the realization of the company's development strategy.
-
The signing amount reached 8.3 billion yuan Zhejiang enterprises to import drugs and medical equipment
Time of Update: 2021-02-27
This signing activity is divided into imported drugs, imported medical supplies, imported medical equipment three links, from AstraZeneca, Sanofi and other imported drug suppliers, Johnson and Johnson, Medtron and other imported medical supplies suppliers and GE, Siemens, Philips and other imported imaging equipment suppliers with Zhejiang Province Pharmaceutical Procurement Center (on behalf of users), 12 provincial hospitals and Dean Diagnostics, American Health, Aibo Health, Tongze Group and other four health services signed the intention to purchase enterprises.
-
5 billion yuan "white medicine" market pattern changes Hengrui 19K into the big
Time of Update: 2021-02-27
According to the experience after the listing of neulasta, the long-term characteristics of the second generation of white medicine products are very competitive, the current domestic G-CSF sample hospital market sales of 998 million yuan, long-acting drugs only 12.62 percent, so the product long-term replacement short-acting space is equally huge.
-
Ali Health's net profit increased by 100% and its consumer healthcare business increased significantly
Time of Update: 2021-02-27
Consumer Healthcare's business improved significantly according to the announcement, Ali Health provided users with an average of more than 1 million medical and health services per day through Alipay, Taobao and other platforms, including payment, registration, online health consulting, etc., while revenue from its consumer healthcare business, including vaccines, oral medicine and medical services, grew 125.1% year-on-year.
-
160 million! Yiyi Pharmaceutical intends to buy a house from the real controller and other people to build an orthopaedic hospital
Time of Update: 2021-02-27
The real controller and other real estate sales can earn 90 million Yiyi Pharmaceuticals announced that the company's wholly-owned subsidiary Yiyi Investment intends to invest 162 million yuan to buy the controlling shareholder, the actual controller, chairman Du Yuling and concerted actors, company directors, senior management Du Yaqi under the name of six properties.
-
Black swans have hit the pharmaceutical sector hard, with the market value evaporating by more than $150 billion in four days
Time of Update: 2021-02-27
Changsheng Bio announced on July 18 that it expects to reduce first-half operating income by about 200 million yuan and net profit by about 140 million yuan due to a recall of all batches of freeze-dried human rabies vaccines during the validity period.
-
Kanghong Pharmaceuticals' first-half profit was 310 million yuan, up 33% YoY
Time of Update: 2021-02-27
From January to June, the Company achieved operating income of RMB1.383 billion, up 1.03% YoY, while net income attributable to shareholders of listed companies was RMB310 million, up 33.13% YoY, and basic earnings per share was RMB0.46.
-
Johnson and Johnson contributed the most to second-quarter revenue of $20.8 billion in cancer drug sales
Time of Update: 2021-02-27
In the second quarter of 2018, Johnson and Johnson generated revenue of $20.8 billion, of which global cancer drug sales rose 42 percent to $2.46 billion.
-
Harpoon's $2 billion acquisition of GNC U.S. agreed
Time of Update: 2021-02-27
After passing the REVIEW of CFIUS, we need to wait for the approval or filing of Heilongjiang National Development and Reform Commission and other regulatory bodies, Ha Pharmaceuticals is not far from
-
The transformation of the pharmaceutical industry accelerates the multi-point flowering of innovative drug research and development
Time of Update: 2021-02-27
The first impression investors gave investors of the 2009 listing was that the business was sound, and that there had not been a year of declining performance in the nine years since the listing. In 2
-
GSK intends to sell its nutrition business to Lihua for $3 billion
Time of Update: 2021-02-27
GlaxoSmithKline's nutrition business includes the popular Horlicks malt beverage brand in India, and Horlicks' product line, which is sold mainly in Asia, is a nutritional supplement to the children's diet.
-
Only Hengrui Pharmaceuticals and Kangmei Pharmaceuticals have a market capitalization of 100 billion yuan
Time of Update: 2021-02-27
as of the close of trading on August 23rd, the only pharmaceutical stocks with a market capitalisation of 100 billion were Hengrui Pharmaceuticals and Kangmei Pharmaceuticals, but so far this year, the rise in Pharmaceuticals Mingkangde, Chipo and Zhifei Bio has been staggering.
-
North China Pharmaceuticals reported a 254.32% year-on-year increase in net profit for the third quarter
Time of Update: 2021-02-27
On October 17, North China Pharmaceuticals released its third-quarter report, reporting that the company's operating income for the January-September period was 7 billion yuan, and the net profit attr
-
Fosun Pharma's net profit decreased by 13.44% in the first three quarters
Time of Update: 2021-02-27
Fosun Pharma explained the decline in net profit in its third-quarter report, saying it was mainly affected by higher investment in innovative research and development and business layout, losses at some participating companies and higher interest expense.
-
HNA investment to terminate major asset restructuring core medical assets listed and then stranded
Time of Update: 2021-02-27
On the evening of October 30, HNA Investment announced that the major asset restructuring plan involving 100% equity in Xinsheng Medical and 70% stake in Cihang Hospital had been terminated due to the lack of completion conditions and timing, and faced greater uncertainty.
